Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;5(2):59-66.
doi: 10.1007/s12281-011-0051-0. Epub 2011 Mar 26.

Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans

Scott W Mueller  1 , Tyree H Kiser  2
Affiliations

Pros and Cons of Extrapolating Animal Data on Antifungal Pharmacodynamics to Humans

Scott W Mueller et al. Curr Fungal Infect Rep. 2011 Jun.

Abstract

Both the incidence of invasive fungal infections and the number of antifungal agents available to clinicians have expanded significantly over the past two decades. Successes with pharmacokinetic and pharmacodynamic evaluations of other antimicrobial agents in animal models and their clinical correlations with patient outcomes have led to an increased number of studies evaluating both old and new antifungal agents. Recently, animal models have successfully defined target pharmacodynamic indices for many antifungal agents and fungal infections, but validation of these targets in human studies is frequently lacking. This article evaluates the potential pros and cons of extrapolating to humans the animal data on antifungal pharmacodynamics.

Keywords: 5-Flucytosine; Amphotericin B; Anidulafungin; Animal model; Caspofungin; Fluconazole; Invasive fungal infection; Isavuconazole; Micafungin; Murine; Pharmacodynamic; Pharmacokinetic; Posaconazole; Rabbit; Voriconazole.

PubMed Disclaimer

Conflict of interest statement

Disclosure Conflicts of Interest: S. Mueller: none; T. Kiser: grants from Pfizer.

References

    1. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998;42:1105–9. - PMC - PubMed
    1. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999;43:2116–20. - PMC - PubMed
    1. Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005;49:3171–7. - PMC - PubMed
    1. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007;51:35–9. - PMC - PubMed
    1. Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003;47:3165–9. - PMC - PubMed

LinkOut - more resources